What it's for (Indications)
- Amlodipine besylate + telmisartan is indicated for the treatment of hypertension in adult patients.
- This fixed-dose combination therapy is typically prescribed when monotherapy with either amlodipine or telmisartan alone has not adequately controlled blood pressure.
- It is also used as initial therapy in patients likely to need multiple agents to achieve their blood pressure goals.
- The synergistic action of these two antihypertensive agents, targeting different pathways, provides more effective blood pressure reduction and improved patient adherence compared to separate medications.
- This combination helps to lower the risk of cardiovascular events, including stroke and myocardial infarction, associated with uncontrolled high blood pressure.
- It is not indicated for the initial treatment of hypertension.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of amlodipine besylate + telmisartan is one tablet orally once daily, with or without food. Dosage should be individualized based on the patient's blood pressure response and tolerability, with gradual titration recommended. Available strengths typically include combinations such as 5 mg amlodipine / 40 mg telmisartan, 5 mg amlodipine / 80 mg telmisartan, 10 mg amlodipine / 40 mg telmisartan, and 10 mg amlodipine / 80 mg telmisartan. The maximum recommended dose of amlodipine is 10 mg daily and telmisartan is 80 mg daily. Patients should be advised to take the medication at approximately the same time each day to maintain consistent therapeutic levels. Dose adjustments may be necessary in patients with renal or hepatic impairment, and concurrent diuretic therapy may necessitate lower initial doses to avoid symptomatic hypotension. |
Safety & Warnings
Common Side Effects
- Common side effects associated with amlodipine besylate + telmisartan include dizziness, lightheadedness, peripheral edema (swelling of ankles/feet, primarily due to amlodipine's vasodilatory effect), headache, and fatigue.
- Other reported adverse events may include flushing, abdominal pain, nausea, and dyspepsia.
- Less common but potentially serious side effects include symptomatic hypotension, syncope, hyperkalemia (due to telmisartan), and angioedema (rarely, due to telmisartan).
- Patients should be advised to report any persistent or worsening side effects to their healthcare provider.
- Immediate medical attention is required for signs of severe allergic reactions like difficulty breathing, swelling of the face, lips, tongue, or throat, or severe dizziness.
- Postural hypotension may also occur, especially upon standing.
Serious Warnings
- Black Box Warning: **FETAL TOXICITY:** Drugs that act directly on the renin-angiotensin system (RAS), such as telmisartan, can cause injury and death to the developing fetus. When pregnancy is detected, amlodipine besylate + telmisartan should be discontinued as soon as possible. There is no satisfactory alternative to drug therapy in these conditions. The use of RAS inhibitors during the second and third trimesters of pregnancy increases fetal and neonatal morbidity and mortality, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios, resulting from decreased fetal renal function, has also been reported and can lead to fetal lung hypoplasia and skeletal deformations. These adverse outcomes are usually associated with the use of RAS inhibitors in these trimesters. Physicians should immediately inform female patients of childbearing age about the potential risks and counsel them to discontinue the medication and consult their healthcare provider if pregnancy is confirmed or suspected to avoid severe and potentially fatal outcomes for the fetus.
- Patients receiving amlodipine besylate + telmisartan therapy should be closely monitored for symptomatic hypotension, especially those who are volume-depleted (e.
- g.
- , due to high-dose diuretics) or salt-depleted.
- Initiation of therapy may require careful titration in these individuals to minimize the risk of a precipitous drop in blood pressure.
- Due to the telmisartan component, transient hypotension may occur in patients with severe congestive heart failure or severe aortic stenosis; caution is advised.
- Renal function should be routinely assessed in patients, especially those with pre-existing renal impairment or renovascular disease, as telmisartan can cause changes in kidney function, including acute renal failure.
- Hyperkalemia is a potential risk, particularly in patients with renal dysfunction, diabetes, or those concurrently using potassium-sparing diuretics, potassium supplements, or other drugs that can increase potassium levels.
- Regular monitoring of serum potassium is recommended.
- Hepatic impairment also requires careful consideration, as telmisartan is primarily eliminated via bile; dosage adjustments may be necessary, and its use is contraindicated in severe hepatic impairment.
- In patients with severe obstructive coronary artery disease, there is a rare risk of increased angina frequency or severity, or acute myocardial infarction upon initiation or dosage increase of amlodipine.
How it Works (Mechanism of Action)
Amlodipine besylate + telmisartan combines two distinct antihypertensive agents with complementary mechanisms of action. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. This causes peripheral arterial vasodilation and a reduction in peripheral vascular resistance, thereby lowering blood pressure. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, which is found in many tissues, including vascular smooth muscle and the adrenal gland. By blocking the AT1 receptor, telmisartan inhibits the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation, decreased aldosterone secretion, and reduced sodium and water reabsorption, contributing to blood pressure reduction. The combination provides a more comprehensive and potent antihypertensive effect by targeting multiple pathways involved in blood pressure regulation, leading to improved blood pressure control compared to monotherapy.
Commercial Brands (Alternatives)
No other brands found for this formula.